Combinations Alliance announce new partner: Immodulon

We are delighted to announce that Immodulon have joined the Combinations Alliance and we look forward to a successful collaboration with them. The agent which Immodulon is currently developing is IMM-101, a multi-modal systemic immunomodulator containing "heat killed" Mycobacterium-obuense-(NCTC 13365) that can help restore effective anti-tumour immune function.

There were early indications of efficacy with IMM-101 in a phase II pancreatic study and Immodulon are open to ideas for novel combinations and indications with strong scientific rationale, while confirmatory studies in pancreatic cancer are undertaken.

For more information on the agent and how to submit an expression of interest visit http://www.ecmcnetwork.org.uk/eoi-calls